ATE401395T1 - Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren - Google Patents

Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren

Info

Publication number
ATE401395T1
ATE401395T1 AT02769340T AT02769340T ATE401395T1 AT E401395 T1 ATE401395 T1 AT E401395T1 AT 02769340 T AT02769340 T AT 02769340T AT 02769340 T AT02769340 T AT 02769340T AT E401395 T1 ATE401395 T1 AT E401395T1
Authority
AT
Austria
Prior art keywords
disorders
diseases
psychiatric
deacetylase inhibitors
treating neurodegenerative
Prior art date
Application number
AT02769340T
Other languages
English (en)
Inventor
Joan Steffan
Leslie Thompson
J Marsh
Laszlo Bodai
Judit Pallos
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE401395T1 publication Critical patent/ATE401395T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/60New or modified breeds of invertebrates
    • A01K67/61Genetically modified invertebrates, e.g. transgenic or polyploid
    • A01K67/65Genetically modified arthropods
    • A01K67/68Genetically modified insects
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
AT02769340T 2001-05-02 2002-05-02 Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren ATE401395T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28821501P 2001-05-02 2001-05-02
US37272402P 2002-04-11 2002-04-11

Publications (1)

Publication Number Publication Date
ATE401395T1 true ATE401395T1 (de) 2008-08-15

Family

ID=26964894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769340T ATE401395T1 (de) 2001-05-02 2002-05-02 Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren

Country Status (5)

Country Link
EP (1) EP1390491B1 (de)
AT (1) ATE401395T1 (de)
DE (1) DE60227658D1 (de)
ES (1) ES2310213T3 (de)
WO (1) WO2002090534A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (de) 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP4790594B2 (ja) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Hdacインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
EP1824831A2 (de) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
JP5156392B2 (ja) 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Hdac阻害剤を用いる併用療法
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
EP1896436A2 (de) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
GB0518235D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
EP1937236A2 (de) * 2005-09-07 2008-07-02 Braincells, Inc. Modulation der neurogenese durch hdac-hemmung
WO2007035029A1 (en) * 2005-09-23 2007-03-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2012801A4 (de) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc Gemcitabin-kombinationstherapie
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2599479A1 (de) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbuttersäure zur Behandlung der Alzheimer-Krankheit
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN103861084A (zh) * 2014-02-12 2014-06-18 新乡医学院 Romidepsin在治疗帕金森病中的应用
US9655910B2 (en) 2014-03-21 2017-05-23 Bodybio Inc. Compositions and methods for treating addiction
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
WO2017096298A1 (en) 2015-12-04 2017-06-08 Regents Of The University Of California Histone deacetylase inhibitors
WO2021060567A1 (en) 2019-09-27 2021-04-01 Takeda Pharmaceutical Company Limited 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto

Also Published As

Publication number Publication date
DE60227658D1 (de) 2008-08-28
WO2002090534A1 (en) 2002-11-14
ES2310213T3 (es) 2009-01-01
EP1390491A4 (de) 2005-04-06
EP1390491A1 (de) 2004-02-25
EP1390491B1 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
ATE401395T1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
TWI263503B (en) Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
ATE493433T1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EA200801711A1 (ru) Пролекарства возбуждающих аминокислот
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE323084T1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
DK1343472T3 (da) Thixotropisk næsespray
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE513471T1 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
ATE376425T1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
BR0317714A (pt) Oxazóis como realçadores de mglur1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390491

Country of ref document: EP